What's new? Log in Free sign up

Valneva SE (VALN)

Company Profile

Company profile

Ticker

VALN

Exchange

Website

CEO

Mr. Thomas Lingelbach

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Biomotion Sciences Ordinary Shares • Amgen • Gilead Sciences • Biogen • Qiagen • Sterling Check • Bio-Techne • Moderna • Acorda Therapeutics • Saratoga Investment ...

Former names

Flying Eagle Acquisition Corp.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

VALN stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

HC Wainwright & Co.

Latest filings (excl ownership)

View all

If granted, IXCHIQ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older

Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook

Current report (foreign)

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million

Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision

Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India

Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal

Current report (foreign)

Transcripts

Earnings call transcript

Earnings call transcript

Latest ownership filings

Bpifrance Participations SA

Deep Track Capital, LP

Bpifrance Participations SA

Bpifrance Participations SA

Deep Track Capital, LP

Bpifrance Participations SA

Financial summary

Financial statements Chart VALN financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Valneva SE earnings reports.

Institutional ownership, Q3 2024

VALN institutional ownership history Ownership history

30.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	10	6	+66.7%
Opened positions	4	2	+100.0%
Closed positions	0	9	EXIT
Increased positions	2	1	+100.0%
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	4.50 bn	1.26 bn	+258.6%
Total shares	24.35 mm	21.26 mm	+14.6%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Bpifrance Participations	14.11 mm	$82.99 mm	+21.5%
PFE Pfizer	9.55 mm	$237.31 mm	0.0%
GAM General American Investors	354.36 k	$2.15 bn	NEW
WFC Wells Fargo & Company	215.91 k	$1.30 bn	NEW
AlphaCentric Advisors	118.00 k	$717.44 mm	+33.7%
Ridgewood Investments	550.00	$3.32 mm	0.0%
AlphaMark Advisors	150.00	$1.00 k	NEW
Advisor	150.00	$906.00 k	NEW
Allworth Financial	7.00	$43.00 k	0.0%
Activest Wealth Management	1.00	$6.00 k	0.0%

Largest transactions	Shares	Bought/sold	Change
Bpifrance Participations	14.11 mm	+2.50 mm	+21.5%
GAM General American Investors	354.36 k	+354.36 k	NEW
WFC Wells Fargo & Company	215.91 k	+215.91 k	NEW
AlphaCentric Advisors	118.00 k	+29.75 k	+33.7%
AlphaMark Advisors	150.00	+150.00	NEW
Advisor	150.00	+150.00	NEW
PFE Pfizer	9.55 mm	0.00	0.0%
Proequities	0.00	0.00
Allworth Financial	7.00	0.00	0.0%
Ridgewood Investments	550.00	0.00	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Valneva, Maintains $17 Price Target

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $17 price target.

4 Analysts Have This To Say About Valneva

HC Wainwright & Co. Maintains Buy on Valneva, Lowers Price Target to $17

HC Wainwright & Co. analyst Edward White maintains Valneva (NASDAQ:VALN) with a Buy and lowers the price target from $18 to $17.

Valneva 2025 Financial Outlook: Sales Revenue Projected At €170M-€180M, Total Revenue To Reach €180M-€190M; R&D Investments Of €90M-€100M

Valneva Preliminary 2024 Revenue €169.6M (+10% YoY), Product Sales Hit €163.3M (+13% YoY); Cash And Cash equivalents €168.3M

Press releases

From Benzinga Pro

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

Saint-Herblain (France), March 3, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA) a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States

Valneva Receives EMA's Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®

If granted, IXCHIQ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 – Valneva SE

Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook

Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023)Strong year-end cash position of €168.3 millionSubstantial clinical and regulatory progress in 2024, leading to multiple

Valneva Receives Marketing Authorization in the UK for the World's First Chikungunya Vaccine, IXCHIQ®

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.